Sleep Cycle AB (SE:SLEEP)
:SLEEP
Top Page
Sleep Cycle AB
(SLEEP)
Select Model
Select Model
Rating:69Neutral
Price Target:
kr18.00
▼(-28.00% Downside)
Action:ReiteratedDate:02/07/26
The score is supported by solid fundamentals (profitability, cash flow, and low leverage) and very attractive valuation (low P/E and high dividend yield). These positives are tempered by weak technicals (downtrend and very low momentum) and the recent revenue slowdown/decline with margin volatility.
Positive Factors
Recurring subscription model
A subscription-first business drives predictable recurring revenue and higher lifetime value versus one-time purchases. This model supports steady cashflow, facilitates retention and upsell, and enables planning for product investment and marketing over a multi-quarter horizon.
Negative Factors
Revenue slowdown
A top-line deceleration interrupts the company’s growth trajectory and challenges the subscription flywheel. Slower user acquisition or conversion can pressure recurring revenue inflows, reduce scale benefits, and constrain reinvestment capacity across ensuing quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Recurring subscription model
A subscription-first business drives predictable recurring revenue and higher lifetime value versus one-time purchases. This model supports steady cashflow, facilitates retention and upsell, and enables planning for product investment and marketing over a multi-quarter horizon.
Read all positive factors
Sleep Cycle AB (SLEEP) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr341.88M
Dividend Yield7.64%
Average Volume (3M)46.23K
Price to Earnings (P/E)9.8
Beta (1Y)0.16
Revenue Growth0.29%
EPS Growth6.80%
CountrySE
Employees33
SectorTechnology
Sector Strength88
IndustrySoftware - Application
Share Statistics
EPS (TTM)0.56
Shares Outstanding20,277,563
10 Day Avg. Volume28,513
30 Day Avg. Volume46,232
Financial Highlights & Ratios
PEG Ratio-0.64
Price to Book (P/B)7.24
Price to Sales (P/S)2.10
P/FCF Ratio9.84
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.08
Revenue Forecast (FY)kr243.45M
Sleep Cycle AB Business Overview & Revenue Model
Company Description
Sleep Cycle AB (SLEEP) is a technology company specializing in sleep tracking and improvement solutions. The company operates primarily in the health and wellness sector, offering a mobile application that analyzes users' sleep patterns and provid...
How the Company Makes Money
Sleep Cycle AB generates revenue primarily through a subscription-based model for its mobile application. Users can access basic features for free, but the company offers premium subscriptions that unlock advanced functionalities, such as detailed...
Sleep Cycle AB Financial Statement Overview
Summary
Income Statement
74
Positive
Balance Sheet
72
Positive
Cash Flow
79
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 247.88M | 261.53M | 236.15M | 213.27M | 182.94M |
| Gross Profit | 121.36M | 201.87M | 128.55M | 156.65M | 141.62M |
| EBITDA | 73.62M | 88.45M | 64.05M | 46.27M | 12.37M |
| Net Income | 53.21M | 62.64M | 46.14M | 33.94M | 8.11M |
Balance Sheet | |||||
| Total Assets | 200.15M | 236.49M | 230.54M | 301.37M | 227.76M |
| Cash, Cash Equivalents and Short-Term Investments | 120.85M | 144.82M | 133.47M | 232.86M | 165.51M |
| Total Debt | 7.38M | 11.74M | 15.92M | 4.20M | 2.49M |
| Total Liabilities | 128.31M | 157.04M | 169.55M | 140.54M | 118.86M |
| Stockholders Equity | 71.83M | 79.46M | 61.00M | 160.83M | 108.90M |
Cash Flow | |||||
| Free Cash Flow | 52.88M | 59.73M | 51.00M | 53.76M | 14.15M |
| Operating Cash Flow | 52.93M | 63.66M | 52.72M | 61.53M | 20.09M |
| Investing Cash Flow | -13.15M | -3.92M | -6.81M | -7.77M | -5.93M |
| Financing Cash Flow | -64.19M | -48.36M | -145.30M | 14.01M | 98.22M |
Sleep Cycle AB Technical Analysis
Neutral
25.00
Price Trends
17.47
Negative
20.78
Negative
24.50
Negative
Market Momentum
-0.08
Negative
50.26
Neutral
76.41
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:SLEEP, the sentiment is Neutral. The current price of 25 is above the 20-day moving average (MA) of 17.05, above the 50-day MA of 17.47, and above the 200-day MA of 24.50, indicating a neutral trend. The MACD of -0.08 indicates Negative momentum. The RSI at 50.26 is Neutral, neither overbought nor oversold. The STOCH value of 76.41 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SE:SLEEP.
Sleep Cycle AB Peers Comparison
UnderperformOutperform
Sector (61)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | kr427.76M | 18.38 | ― | 3.48% | ― | ― | |
69 Neutral | kr341.88M | 9.78 | 96.69% | 7.64% | 0.29% | 6.80% | |
61 Neutral | $37.18B | 12.37 | -10.20% | 1.83% | 8.50% | -7.62% | |
52 Neutral | kr59.95M | 24.78 | ― | ― | ― | ― | |
49 Neutral | kr89.66M | -1.20 | -83.82% | ― | -18.26% | -109.47% | |
49 Neutral | kr217.27M | -0.85 | ― | ― | ― | ― | |
45 Neutral | kr38.90M | -0.07 | ― | ― | ― | ― |
* Technology Sector Average
SE:SLEEP
Sleep Cycle AB
16.86
-23.99
-58.73%
SE:CHECK
Checkin.com Group AB
3.00
-5.52
-64.79%
SE:FLOWS
Flowscape Technology AB
3.06
-0.23
-6.99%
SE:GENI
Generic Sweden AB
34.80
-22.47
-39.23%
SE:MOBA
M.O.B.A. Network AB
1.72
-5.59
-76.51%
SE:BUSER
Bambuser AB
27.00
11.49
74.08%
Sleep Cycle AB Corporate Events
Sleep Cycle leans on health-tech tie-ups as revenue softens
Feb 4, 2026
Sleep Cycle’s 2025 year-end report shows a tightened focus on SDK licensing and health-tech partnerships—highlighted by collaborations with Ultrahuman, a global IoT player, and a CRO-backed AI sleep apnea validation study—even as...
UKHSA Taps Sleep Cycle Data in Bid to Improve Early Detection of Respiratory Outbreaks
Jan 28, 2026
The UK Health Security Agency (UKHSA) and Sleep Cycle have launched a 12-week research collaboration to assess whether anonymised, privacy-preserved data from the Sleep Cycle app and its Cough Radar tool can complement traditional respiratory dise...
Sleep Cycle Moves Sleep Apnea AI Study Validation to US to Bolster Market Push
Jan 23, 2026
Sleep Cycle has signed an agreement with a leading US clinical research organization to run the validation phase of its clinical study for an AI-based sleep apnea screening tool, as the development phase, based on roughly 300 recorded nights, near...
Sleep Cycle Schedules Webcast to Present 2025 Year-End Report
Jan 21, 2026
Sleep Cycle AB will present its year-end report for 2025 via an English-language webcast on 4 February at 09:30 CET, with CEO Erik Jivmark and CFO Head of IR Elisabeth Hedman leading the presentation followed by a QA session for shareholders, med...
Sleep Cycle strikes multi-year IoT licensing deal to expand beyond mobile sleep tracking
Dec 18, 2025
Sleep Cycle has signed a strategic multi-year SDK licensing agreement with a global IoT and smart home device brand, allowing the customer to embed Sleep Cycle’s patented audio-based sleep-tracking analysis directly into its hardware product...
Sleep Cycle Launches Luma: An AI-Powered Health Coach
Dec 3, 2025
Sleep Cycle has launched Luma, an AI-powered health coach that extends beyond traditional sleep tracking to offer personalized guidance connecting sleep to various life goals such as mental health, stress, and productivity. Luma represents a signi...
Sleep Cycle Partners with Urban Sports Club for Holistic Wellness Experience
Nov 20, 2025
Sleep Cycle has announced a new partnership with Urban Sports Club, a leading sports and wellness platform, to offer an integrated wellness experience by combining sleep insights with fitness goals. This collaboration aims to enhance user health b...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.